Combination therapy is changing how doctors identify the highest-risk myeloma patients
Researchers studying multiple myeloma say advances in frontline treatment have changed a basic clinical assumption about which patients face the poorest odds after diagnosis. In a new analysis published in Cancer, investigators argue that physicians should update the definition of so-called functional high-risk disease to reflect what now happens in the era of quadruplet therapy and stem cell transplantation.
The shift is subtle in wording but significant in practice. Functional high-risk, often shortened to FHR, has traditionally referred to multiple myeloma that progresses within 18 months of starting treatment and is associated with survival of less than two years after that progression. The new study suggests that threshold no longer captures the right group once patients are treated with modern four-part regimens and autologous stem cell transplantation.
Instead, the researchers found that progression within 36 months of starting treatment better identified patients whose survival after progression was likely to remain under two years. They refer to this updated population as “FHR36.”
Why the old definition may now be outdated
Multiple myeloma is a serious blood cancer, and its course can vary sharply between patients. One of the most important tasks in treatment planning is figuring out early who is likely to do poorly despite aggressive therapy. That allows clinicians to steer those patients toward more intensive options or research studies before the disease becomes even harder to control.
But when the standard of care changes, the warning signs can change with it. According to the study summary, the growing use of an upfront regimen combining anti-CD38 antibodies, proteasome inhibitors, immunomodulatory agents, and dexamethasone, followed by autologous stem cell transplantation, has helped delay progression compared with earlier treatment eras.
That means a patient who relapses after, for example, two years might still belong to a high-risk group under contemporary treatment patterns, even if they would not have met the older 18-month definition. The study’s premise is that clinicians need a risk signal calibrated to the therapies patients actually receive today, not to a previous generation of treatment.
What the researchers analyzed
The investigators came from the University of Alabama at Birmingham and the CoMMiT consortium. They examined data from 310 patients with newly diagnosed multiple myeloma who received the modern treatment combination and were followed for a median of 3.5 years.
Within that cohort, survival analyses showed that progression within 36 months of starting combination therapy identified the subgroup whose survival after progression was likely to be less than two years. In other words, the clinically meaningful cut point expanded from 18 months to three years in this treatment setting.
The researchers reported that this FHR36 population represented 16.4% of all treated patients in the study. That is not a majority, but it is large enough to matter for how clinical trials are designed and how scarce advanced therapies are prioritized.
What this means for treatment strategy
The paper does not present the new definition as an abstract labeling exercise. It links the revised classification directly to decisions about who should be considered sooner for additional treatment approaches, especially T-cell redirecting therapy.
According to the source text, adding T-cell redirecting therapy helped slow progression. Based on that result, the authors argue that patients falling into the FHR36 group should be prioritized for early use of these therapies as well as for clinical trials testing drugs with novel mechanisms of action.
This is an important point because modern oncology increasingly depends on matching patients to the right level of intervention at the right time. A risk definition that is too narrow may miss people whose disease is clearly behaving aggressively under current treatment standards. A definition that is too broad can dilute trials and expose patients to therapies they may not need yet. The proposed 36-month window is an attempt to sharpen that line using recent real-world outcomes from patients treated in the current era.
Implications for trials and clinical decision-making
The revised framework could influence research as much as bedside care. High-risk populations are often the ones targeted for next-generation studies because they have the most urgent need for better options and because treatment effects can be more visible in groups with poorer expected outcomes.
If clinicians and researchers adopt FHR36, enrollment criteria for future myeloma trials may shift accordingly. Rather than focusing primarily on patients who progress within 18 months, studies could cast a wider but still biologically and clinically meaningful net, bringing in people who relapse within three years after modern induction treatment and transplant.
That would align trial populations more closely with the realities of current practice. It could also make it easier to test whether newer immunotherapies or other novel agents work best when deployed earlier in the course of a high-risk relapse pattern.
Senior author Dr. Luciano J. Costa said the findings should help physicians choose therapies for this minority of patients and identify a population whose need for treatment innovation should be addressed in the next generation of clinical trials. That summary captures the paper’s practical message: risk definitions are not static, and if treatment improves, the thresholds used to flag danger must be revisited.
A narrower group, but a clearer target
The study does not claim to solve multiple myeloma’s hardest problems, and it does not suggest that every patient progressing within three years will respond the same way to intensified therapy. What it does provide is an updated lens for recognizing a subgroup that still fares poorly even after receiving a powerful frontline regimen.
That is valuable because it helps keep oncology classifications tied to actual patient outcomes rather than historical habit. As combination therapies extend disease control for many people, the definition of “high risk” has to move with them. In this case, the proposed move is from 18 months to 36 months, from an older treatment era to a newer one, and from a broad concern about relapse to a more concrete call for earlier access to innovative therapy for patients most likely to need it.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
